Related Experiment Video
Updated: Jan 6, 2026

Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
Published on: August 17, 2022
Update on Prenatal Laboratory Screening: Joint Commission Required Elements
Jared L Tepper1, Karen M Puopolo2,3,4
1Department of Obstetrics and Gynecology and.
Insights
Routine screening for pregnant women for infections like HIV, hepatitis B, syphilis, and group B Streptococcus is crucial. New guidelines mandate documentation and peripartum testing to prevent maternal and neonatal morbidity.
Area of Science:
- Obstetrics and Gynecology
- Maternal-Fetal Medicine
- Infectious Disease Prevention
Background:
- Routine prenatal screening for HIV, hepatitis B, syphilis, and group B Streptococcus is recommended by leading health organizations.
- Inadequate prenatal care and screening for these pathogens occur in a significant number of US women.
- Timely identification of maternal infection is critical for preventing vertical transmission and reducing maternal and neonatal morbidity.
Purpose of the Study:
- To highlight the importance of timely screening and documentation of maternal infectious disease status.
- To emphasize the role of labor and delivery units in identifying at-risk pregnant women and infants.
- To outline new Joint Commission guidance aimed at optimizing maternal and neonatal health outcomes.
Main Methods:
- Review of current recommendations from CDC, ACOG, and AAP for prenatal screening.
- Analysis of Joint Commission's 2018 guidance on maternal disease status documentation.
- Focus on peripartum testing for women with inadequate prenatal screening.
Main Results:
- New Joint Commission guidance mandates documentation of maternal disease status and positive newborn results.
- Immediate peripartum testing is required for pregnant women with inadequate screening.
- These measures aim to facilitate timely interventions for maternal health and prevent perinatal transmission.
Conclusions:
- Improved documentation and peripartum testing can enhance maternal and neonatal health outcomes.
- Optimizing screening and timely interventions are key to preventing perinatal infections.
- Adherence to new guidelines is essential for reducing maternal and neonatal morbidity.
Abstract:
The Centers for Disease Control and Prevention, the American College of Obstetricians and Gynecologists, and the American Academy of Pediatrics recommend routine screening for pregnant women for evidence of infection with human immunodeficiency virus, hepatitis B and syphilis, and vaginal-rectal colonization with group B Streptococcus For each of these pathogens, there are important opportunities to provide maternal treatment, prevent vertical transmission of the pathogen during the prenatal or intrapartum periods, and/or administer neonatal treatment immediately after birth. Such prevention and/or treatment measures are critical to limiting maternal and neonatal morbidity; however, this is dependent on recognition of maternal disease status. A significant number of women in the United States receive either inadequate prenatal care or inadequate screening for these pathogens. The time of admission to labor and delivery units represents an important opportunity to detect at-risk pregnant women and infants. To optimize both maternal and neonatal health, the Joint Commission issued new guidance effective July 1, 2018, mandating documentation of maternal disease status for these pathogens in the maternal medical record and documentation of positive results in the newborn medical record. Immediate peripartum testing for women with inadequate screening is also required. These measures should allow for timely interventions to improve maternal health and ideally to prevent perinatal disease transmission to the newborn.
Related Concept Videos
Preventive Healthcare Services
Standards of Care II
Standards of Care I
Serum Laboratory Studies, Stool Test, Breath Test
Teratogenicity
Pre-Procedural Guidelines for Assessing Blood Pressure

